Healthcare union members protest N.Y. hospital's contract | Watertown (N.Y.) Daily Times
Dozens of nurses, technical workers and other members of the 1199 SEIU United Healthcare Workers East, the largest healthcare union in the nation, protested hospital management for proposing a decrease in benefits in their latest contract during an informational picket Tuesday afternoon at Canton-Potsdam Hospital.
New Jersey provider plans to open 9 satellite ER departments | NJ.com
CarePoint Health has applied with the state Department of Health to open facilities in the Greenville section of Jersey City, Downtown Jersey City, Union City and North Bergen in Hudson County.
Anthem is cutting out-of-network health coverage in a 'bait and switch,' lawsuit says | Los Angeles Times
On the first day of Obamacare open enrollment, a consumer group sued Anthem Blue Cross for attempting to automatically renew policies that no longer cover out-of-network costs for hundreds of thousands of Californians.
Mass. biotech Nimbus nets $200M from Gilead | Boston Business Journal
Cambridge, Mass.-based Nimbus Therapeutics is stacking another $200 million after its partner Gilead Sciences funded new research for the treatment of non-alcoholic steatohepatitis. Gilead acquired the drug last year, and could eventually pay up to $800 million if more research milestones are reached
Blue Shield again owes Californians millions in healthcare rebates | Kaiser Health News
About 240,000 Californians with job-based health coverage may have been surprised by a recent letter from Blue Shield of California saying the company owes them money, not the other way around.
Dealmakers behind soaring drug prices hit the jackpot | Bloomberg
Dealmakers have always flipped companies. Lately, they've been flipping something else: aging pharmaceuticals.
Sanders sinks drug company's stock with tweet | The Hill
Eli Lilly's stock dropped nearly 2 percentage points after Sanders criticized the rising price of the company's Humalog brand insulin, citing a Washington Post report on soaring costs of the diabetes drug.
